Drug Profile
Research programme: Duchenne muscular dystrophy therapeutics - Aceragen/Parent Project Muscular Dystrophy
Latest Information Update: 20 Jan 2023
Price :
$50
*
At a glance
- Originator Idera Pharmaceuticals
- Developer Aceragen
- Class Nucleic acids
- Mechanism of Action Toll-like receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Duchenne muscular dystrophy